From sale withdrawn all medication with valsartan

Pharmaceutical company Mylan has withdrawn from sale all medicines against high blood pressure, containing valsartan. Laboratory tests found traces of a possible carcinogen in these pills.

Pharmaceutical company Mylan withdraws from U.S. sales of all medicinal products designed to combat high blood pressure, which contain valsartan. Two weeks ago, the company has withdrawn part of these drugs when their composition is found a residual concentration of a chemical that causes cancer. Sanitary control of food and drug administration believes that the presence of a carcinogen may cause changes in the techniques of production of medicines.

On Tuesday, Mylan announced the recall of another 104 names of drugs in addition to those 15 which have already been withdrawn. Magicforum recalls that valsartan is intended for the treatment of high blood pressure and heart failure, as well as reducing the risk of death after a heart attack. It belongs to the class of medications known as angiotensin receptor blockers, which block the natural hormone angiotensin II, constricting arteries. With the use of valsartan in combination with amlodipine or gidrohlortiazidom is achieved only isolated the effect of lowering blood pressure.

Mylan laboratory tests showed that valsartan there are residual traces of a substance called N-nitrosodimethylamine (NDMA). This ingredient is also contained in tobacco smoke, NDMA considered a possible human carcinogen. Note that the products on the basis of the valsartan is not the first time revoked by pharmaceutical companies from sales in connection with the possible content of carcinogens. (READ MORE)